GlassScriptPhysician profile
Anna Perlik
NPI 1063837193
$5,359.57
in general payments reported to CMS, 2019-2025
40 companies · $418 in 2025
The $418 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,591 · 2022: $274 · 2023: $599 · 2024: $478 · 2025: $418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,494.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $613.83 | 2021-2024 | Farxiga |
| Lundbeck LLC | $532.98 | 2022-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $370.71 | 2021-2025 | Uzedy |
| Janssen Pharmaceuticals, INC | $361.94 | 2021-2025 | Invega Sustenna, Spravato |
| Abbvie INC. | $349.77 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $341.48 | 2023-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $280.41 | 2021 | |
| Novo Nordisk INC | $250.37 | 2021-2023 | Wegovy |
| Takeda Pharmaceuticals U.S.A., INC. | $235.81 | 2021 | |
| Lilly USA, LLC | $173.45 | 2021 | |
| Indivior INC. | $159.32 | 2022-2024 | Perseris |
| Esperion Therapeutics, INC. | $153.35 | 2021 | |
| Eisai INC. | $137.63 | 2021 | |
| Alkermes, INC. | $135.23 | 2022-2025 | Aristada, Lybalvi, Vivitrol |
| Glaxosmithkline, LLC. | $123.18 | 2021 |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $111.25 | 2021 | |
| Mylan Specialty L.P. | $94.98 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.91 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $77.51 | 2021 | |
| Sanofi-Aventis U.S. LLC | $73.79 | 2021 | |
| Dexcom, INC. | $73.73 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $70.03 | 2021 | |
| Horizon Therapeutics Plc | $57.73 | 2021 | |
| Avanir Pharmaceuticals, INC. | $57.63 | 2021 | |
| Amgen INC. | $57.48 | 2021 | |
| Scilex Pharmaceuticals INC. | $55.92 | 2021 | |
| Arbor Pharmaceuticals, INC. | $49.80 | 2021 | |
| Amarin Pharma, INC. | $43.18 | 2021 | |
| Nestle Healthcare Nutrition INC. | $41.21 | 2021 | |
| Paratek Pharmaceuticals, INC. | $38.94 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.00 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.39 | 2021 | |
| Abbott Laboratories | $15.66 | 2021 | |
| Genentech USA, INC. | $14.44 | 2021 | |
| Biodelivery Sciences International, INC. | $13.81 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.60 | 2021 | |
| Astellas Pharma US INC | $13.52 | 2021 | |
| Jazz Pharmaceuticals INC. | $13.13 | 2021 | |
| Aytu Biopharma, INC. | $12.43 | 2021 | |
| Currax Pharmaceuticals LLC | $12.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Perlik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.